Free Trial
→ A free stock pick, from me to you (From Behind the Markets) (Ad)tc pixel
OTCMKTS:EFTR

eFFECTOR Therapeutics Q4 2023 Earnings Results & Report

eFFECTOR Therapeutics logo
$0.0008 0.00 (0.00%)
As of 11/9/2026

eFFECTOR Therapeutics missed analyst earnings expectations in its Q4 2023 results, released March 25, 2024. The company reported EPS of -$3.42 versus the -$2.73 consensus estimate.

Research:Profile

Earnings Announcement Details

Quarter
Q4 2023
Report Date

eFFECTOR Therapeutics EPS Results

Actual EPS
-$3.42
Consensus EPS
-$2.73
Beat/Miss
Missed by -$0.69
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

eFFECTOR Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

eFFECTOR Therapeutics' next earnings date is estimated for Tuesday, November 17, 2026, based on past reporting schedules.

Conference Call Resources

eFFECTOR Therapeutics Q4 2023 Earnings FAQ

eFFECTOR Therapeutics (OTCMKTS:EFTR) reported earnings of -$3.42 per share for Q4 2023, missing the consensus estimate of -$2.73. The report was announced on Monday, March 25, 2024.

eFFECTOR Therapeutics' next earnings date is estimated for Tuesday, November 17, 2026. MarketBeat tracks confirmed and estimated earnings dates for eFFECTOR Therapeutics on the company's earnings history page.

eFFECTOR Therapeutics Earnings Headlines

EFTR - eFFECTOR Therapeutics, Inc.
September 25, 2026  |  seekingalpha.comhttps://seekingalpha.com/symbol/EFTR
eFFECTOR Therapeutics (OTC:EFTR) Stock, Insider Trading Activity
October 5, 2024  |  benzinga.comhttps://www.benzinga.com/quote/EFTR/insider-trades
Many investors are about to lose everything
Twenty five years ago, this analyst predicted the fiber optic boom and called Amazon before it became a household name. Now he says a similar shift is unfolding in AI infrastructure. Hundreds of billions are pouring into AI data centers, but he warns the builders could get crushed by their own costs while one overlooked sector absorbs the spending.tc pixel
November 10 at 1:00 AM  |  Porter & Company (Ad)
3 Publicly Traded Companies Filing for Bankruptcy as July Kicks Off
July 15, 2024  |  investorplace.comhttps://investorplace.com/2024/07/3-publicly-traded-companies-filing-for-bankruptcy-as-july-kicks-off/
eFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq
June 24, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/06/24/2902850/0/en/effector-therapeutics-announces-it-will-wind-down-operations-as-it-seeks-strategic-alternatives-and-expects-to-be-delisted-from-nasdaq.html
eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer
May 20, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/05/20/2884841/0/en/effector-therapeutics-to-collaborate-with-the-dana-farber-cancer-institute-on-an-investigator-sponsored-phase-2-clinical-trial-evaluating-zotatifin-as-combination-treatment-in-er-e.html
See More eFFECTOR Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like eFFECTOR Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on eFFECTOR Therapeutics and other key companies, straight to your email.

About eFFECTOR Therapeutics

eFFECTOR Therapeutics (OTCMKTS:EFTR) is a clinical-stage biopharmaceutical company focused on developing medicines that regulate protein production within cancer cells. Its approach, known as translation control, is designed to interfere with the mechanisms cancer cells use to produce proteins needed for growth, survival and resistance to treatment.

The company’s investigational pipeline has included zotatifin (eFT226), an inhibitor of the eukaryotic initiation factor 4A (eIF4A), and tomivosertib (eFT508), an inhibitor of mitogen-activated protein kinase-interacting kinases 1 and 2 (MNK1/2). These programs have been studied as potential treatments for solid tumors and other cancers, both as standalone therapies and in combination with existing treatments.

Founded in 2012 and headquartered in San Diego, California, eFFECTOR has operated primarily as a research and development company serving the oncology biopharmaceutical market. The company was led by co-founder Steven A. Worland, who has served as president and chief executive officer. Its therapies remain investigational and are subject to clinical development and regulatory review.

View eFFECTOR Therapeutics Profile
Earnings Tools